# A Clinical Trial for the Treatment of Carbapenem Resistant Gram-negative Bacterial Infection With Colistimethate Sodium for Injection

> **NCT06198764** · PHASE3 · UNKNOWN · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 80 (estimated)

## Conditions studied

- Mental Health Issue

## Interventions

- **DRUG:** Colistimethate sodium for injection
- **DRUG:** Meropenem for Injection
- **DRUG:** Coly Mycin M Injectable Product

## Key facts

- **NCT ID:** NCT06198764
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-07-06
- **Primary completion:** 2026-03
- **Final completion:** 2026-03
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2024-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06198764

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06198764, "A Clinical Trial for the Treatment of Carbapenem Resistant Gram-negative Bacterial Infection With Colistimethate Sodium for Injection". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06198764. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*